Immunome, Inc. - IMNM STOCK NEWS

Immunome, Inc. (Nasdaq: IMNM) reported third-quarter 2022 financial results, showcasing a net loss of $8.5 million and R&D expenses of $5.2 million. As of September 30, 2022, the company held $27.1 million in cash. Immunome is advancing its clinical trial for the COVID-19 antibody, IMM-BCP-01, and plans to submit an IND for the oncology product, IMM-ONC-01, by mid-2023. The company also presented promising preclinical data on the anti-EPN1 antibody, IMM20059, indicating potential for tumor regression when combined with an existing treatment.

Immunome presented preclinical results for IMM20059, an anti-epsin 1 (EPN1) antibody, at the Society for Immunotherapy of Cancer's annual meeting in Boston. The antibody showed significant effectiveness, achieving over a 50% reduction in tumor volume when combined with atezolizumab compared to individual treatments. EPN1 is upregulated in multiple cancers, indicating potential for improved therapeutic responses. Further studies will explore the combinatorial effects of IMM20059 and anti-PD-L1 treatment.

Immunome, Inc. (NASDAQ: IMNM) announced a peer-reviewed study in Clinical & Translational Immunology, focusing on B cell repertoires in breast cancer patients. The study, conducted with the University of Vermont and the University of Pennsylvania, explores tumor-specific B cell clonal lineages. Key findings include increased frequencies of tumor-specific B cells in tumors versus blood, and insights into the relationship between tumor features and B cell targeting. Immunome aims to leverage these findings for innovative cancer therapies.

Immunome, a biopharmaceutical firm, reported its Q2 2022 results, marking its transition into a clinical stage company. The company continues to dose patients in its Phase 1b study of the COVID-19 antibody cocktail, IMM-BCP-01, which retains neutralizing activity against prevalent Omicron subvariants. Immunome also provided updates on its oncology candidate, IMM-ONC-01, emphasizing its potential in multiple cancers. Financially, R&D expenses were $5.7 million, with a net loss of $8.9 million. Cash reserves stood at $34.6 million as of June 30, 2022.

Immunome Inc. (NASDAQ: IMNM) announces that its COVID-19 therapeutic, IMM-BCP-01, showed effectiveness against the BA.4/5 and BA.2.12.1 subvariants in recent pseudovirus tests. This three-antibody cocktail is currently in Phase 1b clinical trials, with topline data expected in the second half of 2022. Funded by the U.S. Department of Defense, the investigational treatment aims to address the ongoing pandemic. As of June 25, 2022, these subvariants constituted over 90% of COVID-19 cases in the U.S.

Immunome (NASDAQ: IMNM) has initiated a Phase 1b clinical trial of its antibody cocktail, IMM-BCP-01, for treating COVID-19, with the first patient dosed. The study focuses on safety as the primary endpoint, assessing pharmacokinetics and virology as secondary outcomes. Topline results are expected later this year. Previous data indicates that IMM-BCP-01 effectively targets Omicron variants in vitro. The trial is funded by the U.S. Department of Defense, underscoring its significance in combating COVID-19.

Immunome, Inc. (NASDAQ: IMNM) has announced that its President and CEO, Purnanand Sarma, PhD, will present at the Jefferies Healthcare Conference on June 9 at 2:30 p.m. ET. The event will be accessible via a live audio webcast on the company's website, with a replay available for 90 days post-event. Immunome focuses on developing first-in-class antibody therapeutics using its human memory B cell platform, targeting oncology and infectious diseases, including COVID-19. For more details, visit www.immunome.com.

Immunome, Inc. (Nasdaq: IMNM) announced significant advancements in its lead oncology program, IMM-ONC-01, a novel therapy targeting the immunosuppressive cytokine IL-38. Preclinical research shows high mRNA expression of IL-38 in over 60 cancer sub-types, particularly in high unmet need cancers like Gastroesophageal and Head and Neck Squamous Carcinomas. Immunome collaborates with Fox Chase Cancer Center to confirm IL-38 protein expression in patients. The company plans to file an IND in 2H 2022 to expedite clinical development.

Immunome, Inc. (Nasdaq: IMNM) announced promising results from its COVID-19 antibody cocktail, IMM-BCP-01, which effectively neutralized the Omicron variant in in vivo studies with hamsters. The antibody IMM20253 also showed effectiveness against the BA.2 subvariant in in vitro tests. The research indicates that the cocktail retains substantial activity against various Omicron subvariants, enhancing confidence in their Phase 1b study. The study is supported by the U.S. Department of Defense.